Topics

Generex Biotechnology Expands Medical Device & Wound Care Portfolio with Acquisition of Regentys Corporation

08:30 EST 29 Nov 2018 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
Acquisition of Clinical Stage Developer of A Novel Hydrogel for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases Generex Biotechnology Corporation (OTCMKTS:GNBT) is pleased to announce that the compa...

Other Sources for this Article

Generex Biotechnology Corporation
Joseph Moscato
646-599-6222

Todd Falls
800-391-6755 Extension 222
investor@generex.com

Regentys Corporation
Rick Bulman CEO
844-432-7262
rbulman@regentys.com

Russo Partners
Investor / Media Contacts:
Alex Fudukidis
646-942-5632
alex.fudukidis@russopartnersllc.com

Caroline Cunningham
212-845-4292
Caroline.Cunningham@russopartnersllc.com

NEXT ARTICLE

More From BioPortfolio on "Generex Biotechnology Expands Medical Device & Wound Care Portfolio with Acquisition of Regentys Corporation"

Quick Search

Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...